AGIO
Price
$39.51
Change
+$0.44 (+1.13%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
2.26B
21 days until earnings call
ANAB
Price
$26.11
Change
+$0.37 (+1.44%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
756.25M
32 days until earnings call
Interact to see
Advertisement

AGIO vs ANAB

Header iconAGIO vs ANAB Comparison
Open Charts AGIO vs ANABBanner chart's image
Agios Pharmaceuticals
Price$39.51
Change+$0.44 (+1.13%)
Volume$19.61K
Capitalization2.26B
AnaptysBio
Price$26.11
Change+$0.37 (+1.44%)
Volume$5.65K
Capitalization756.25M
AGIO vs ANAB Comparison Chart in %
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. ANAB commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a StrongBuy and ANAB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (AGIO: $39.07 vs. ANAB: $25.74)
Brand notoriety: AGIO and ANAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 220% vs. ANAB: 154%
Market capitalization -- AGIO: $2.26B vs. ANAB: $756.25M
AGIO [@Biotechnology] is valued at $2.26B. ANAB’s [@Biotechnology] market capitalization is $756.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileANAB’s FA Score has 0 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • ANAB’s FA Score: 0 green, 5 red.
According to our system of comparison, AGIO is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while ANAB’s TA Score has 5 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 4 bearish.
  • ANAB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than AGIO.

Price Growth

AGIO (@Biotechnology) experienced а +10.52% price change this week, while ANAB (@Biotechnology) price change was +7.79% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.89%. For the same industry, the average monthly price growth was +16.25%, and the average quarterly price growth was +20.89%.

Reported Earning Dates

AGIO is expected to report earnings on Oct 30, 2025.

ANAB is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+9.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGIO($2.26B) has a higher market cap than ANAB($756M). ANAB YTD gains are higher at: 94.411 vs. AGIO (18.898). ANAB has higher annual earnings (EBITDA): -76.35M vs. AGIO (-434.71M). AGIO has more cash in the bank: 893M vs. ANAB (340M). ANAB has less debt than AGIO: ANAB (15.6M) vs AGIO (52.9M). ANAB has higher revenues than AGIO: ANAB (112M) vs AGIO (37M).
AGIOANABAGIO / ANAB
Capitalization2.26B756M299%
EBITDA-434.71M-76.35M569%
Gain YTD18.89894.41120%
P/E Ratio3.43N/A-
Revenue37M112M33%
Total Cash893M340M263%
Total Debt52.9M15.6M339%
FUNDAMENTALS RATINGS
AGIO vs ANAB: Fundamental Ratings
AGIO
ANAB
OUTLOOK RATING
1..100
6761
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
10077
SMR RATING
1..100
17100
PRICE GROWTH RATING
1..100
4740
P/E GROWTH RATING
1..100
7177
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (43) in the Biotechnology industry is somewhat better than the same rating for ANAB (86). This means that AGIO’s stock grew somewhat faster than ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (77) in the Biotechnology industry is in the same range as AGIO (100). This means that ANAB’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's SMR Rating (17) in the Biotechnology industry is significantly better than the same rating for ANAB (100). This means that AGIO’s stock grew significantly faster than ANAB’s over the last 12 months.

ANAB's Price Growth Rating (40) in the Biotechnology industry is in the same range as AGIO (47). This means that ANAB’s stock grew similarly to AGIO’s over the last 12 months.

AGIO's P/E Growth Rating (71) in the Biotechnology industry is in the same range as ANAB (77). This means that AGIO’s stock grew similarly to ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOANAB
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 11 days ago
76%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ANAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CGRNX32.32N/A
N/A
Invesco Comstock Select R
ACEIX10.91N/A
N/A
Invesco Equity and Income A
MWELX47.56N/A
N/A
MFS Global Equity R4
PZVSX13.26N/A
N/A
Pzena Small Cap Value Investor
DESGX23.75N/A
N/A
DWS ESG Core Equity Institutional

ANAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with QTTB. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANAB
1D Price
Change %
ANAB100%
+6.14%
QTTB - ANAB
43%
Loosely correlated
+8.63%
ADCT - ANAB
38%
Loosely correlated
+9.76%
AMRN - ANAB
38%
Loosely correlated
+2.97%
AGIO - ANAB
36%
Loosely correlated
+7.69%
CLRB - ANAB
36%
Loosely correlated
+3.19%
More